Skip to content
naulon

No noticeNo retraction, correction or concern found when last checked on Nov 16, 2026.

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes

SY Loh, P Mistry, LR Kelland and 2 more

British Journal of Cancer · 1992

doi:10.1038/bjc.1992.419 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Acquired resistance to cisplatin (cis-diamminedichloroplatinum (II)) has been generated in vitro in the 41M human ovarian carcinoma cell line, established from a previously untreated patient. Three cisplatin-resistant variants were selected at approximately 2, 4 and 6-fold resistance (in terms of 50% inhibitory concentrations), in order to study the underlying mechanisms of acquired cisplatin resistance. Compared to the parent line, platinum accumulation following exposure to equimolar concentrations of cisplatin was on average (across the entire concentration range) 2.9, 3.6 and 4.8-fold lower in the 41McisR2, 41McisR4 and 41McisR6 cell lines, respectively. Thus the difference in uptake corresponded closely with their resistance factor in the three resistant variants. Moreover, a significant reduction in platinum accumulation was observed as early as 5 min after exposure to cisplatin in the 41M vs 41McisR6 cell lines. Platinum accumulation was similar in all cell lines following exposure to equitoxic concentrations (2 h IC50) of cisplatin. Enhanced efflux of drug was not observed between the 41M and 41McisR6 cells. In addition, there was no difference in intracellular glutathione (GSH) levels. Our previous studies have shown no indication of metallothionein involvement and the decrease in cisplatin uptake in the 41McisR6 cells was reflected by a similar reduction in DNA interstrand cross-links (ISC) formation. These results suggest that the mechanism of acquired resistance to cisplatin in the 41McisR6 cell line may be predominantly due to reduced drug uptake. The 41McisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of sodium-potassium adenosine triphosphatase (Na+, K(+)-ATPase), suggesting that decreased cisplatin accumulation in these cells is probably not regulated by alterations in their Na+, K(+)-ATPase levels, and Na+ potential across the plasma membrane. Cellular accumulation of a novel class of platinum (IV) ammine/cyclohexylamine dicarboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to cisplatin in the 41McisR line, was also examined. The data suggests that increased accumulation of these compounds, as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency over cisplatin.

Abstract licence: CC BY

References33

  1. 1.

    Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990;2(2):35-43.

    Not in our library

  2. 2.

    Andrews P. A., Jones J. A., Varki N. M., Howell S. B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun. 1990;2(2):93-100.

    Not in our library10.3727/095535490820874641 (opens in a new tab)

  3. 3.

    Andrews P. A., Mann S. C., Huynh H. H., Albright K. D. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res. 1991;51(14):3677-3681.

    Not in our library

  4. 4.

    Andrews P. A., Murphy M. P., Howell S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 1985;45(12 Pt 1):6250-6253.

    Not in our library

  5. 5.

    Andrews P. A., Velury S., Mann S. C., Howell S. B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1988;48(1):68-73.

    Not in our library

  6. 6.

    Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984;44(10):4224-4232.

    Not in our library

  7. 7.

    Bernal S. D., Speak J. A., Boeheim K., Dreyfuss A. I., Wright J. E., Teicher B. A., Rosowsky A., Tsao S. W., Wong Y. C. Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biochem. 1990;95(1):61-70.

    Not in our library10.1007/bf00219531 (opens in a new tab)

  8. 8.

    Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Harrap K. R. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985;12(Suppl A):51-57.

    Not in our library10.1016/0305-7372(85)90018-0 (opens in a new tab)

  9. 9.

    Eichholtz-Wirth H., Hietel B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer. 1986;54(2):239-243.

    Not in our library10.1038/bjc.1986.168 (opens in a new tab)

  10. 10.

    Green J. A., Vistica D. T., Young R. C., Hamilton T. C., Rogan A. M., Ozols R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 1984;44(11):5427-5431.

    Not in our library

  11. 11.

    Harrap K. R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev. 1985;12(Suppl A):21-33.

    Not in our library10.1016/0305-7372(85)90015-5 (opens in a new tab)

  12. 12.

    Hecquet B., Leroy A., Lefebvre J. L., Peyrat J. P., Adenis L. Uptake of platinum compounds in human tumors. In vitro study. Bull Cancer. 1986;73(5):535-541.

    Not in our library

  13. 13.
  14. 14.

    Hospers G. A., Mulder N. H., de Jong B., de Ley L., Uges D. R., Fichtinger-Schepman A. M., Scheper R. J., de Vries E. G. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res. 1988;48(23):6803-6807.

    Not in our library

  15. 15.

    Hromas R. A., North J. A., Burns C. P. Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett. 1987;36(2):197-201.

    Not in our library10.1016/0304-3835(87)90091-7 (opens in a new tab)

  16. 16.

    Kawai K., Kamatani N., Georges E., Ling V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J Biol Chem. 1990;265(22):13137-13142.

    Not in our library

  17. 17.

    Kawai K., Kamatani N., Kuroshima S., Nobori T., Nishioka K., Kamiya H., Sakurai M., Mikanagi K. Cross-resistance to ouabain in a murine leukemia cell variant selected for cis-dichlorodiammineplatinum(II) resistance. Cancer Lett. 1987;35(2):147-152.

    Not in our library10.1016/0304-3835(87)90038-3 (opens in a new tab)

  18. 18.

    Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992;52(14):3857-3864.

    Not in our library

  19. 19.

    Kelland L. R., Murrer B. A., Abel G., Giandomenico C. M., Mistry P., Harrap K. R. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1992;52(4):822-828.

    Not in our library

  20. 20.

    Kikuchi Y., Iwano I., Miyauchi M., Sasa H., Nagata I., Kuki E. Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 1990;39(2):199-203.

    Not in our library10.1016/0090-8258(90)90432-k (opens in a new tab)

  21. 21.

    Kraker A. J., Moore C. W. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res. 1988;48(1):9-13.

    Not in our library

  22. 22.

    LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-275.

    Not in our library

  23. 23.

    Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984;100(5):704-713.

    Not in our library10.7326/0003-4819-100-5-704 (opens in a new tab)

  24. 24.

    Louie K. G., Behrens B. C., Kinsella T. J., Hamilton T. C., Grotzinger K. R., McKoy W. M., Winker M. A., Ozols R. F. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 1985;45(5):2110-2115.

    Not in our library

  25. 25.

    Mann S. C., Andrews P. A., Howell S. B. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol. 1990;25(4):236-240.

    Not in our library10.1007/bf00684878 (opens in a new tab)

  26. 26.

    Metcalfe S. A., Cain K., Hill B. T. Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett. 1986;31(2):163-169.

    Not in our library10.1016/0304-3835(86)90007-8 (opens in a new tab)

  27. 27.
  28. 28.

    Morikage T., Bungo M., Inomata M., Yoshida M., Ohmori T., Fujiwara Y., Nishio K., Saijo N. Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J Cancer Res. 1991;82(6):747-751.

    Not in our library10.1111/j.1349-7006.1991.tb01912.x (opens in a new tab)

  29. 29.

    Ozols R. F., Young R. C. Chemotherapy of ovarian cancer. Semin Oncol. 1984;11(3):251-263.

    Not in our library

  30. 30.

    Richon V. M., Schulte N., Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res. 1987;47(8):2056-2061.

    Not in our library

  31. 31.

    Teicher B. A., Holden S. A., Kelley M. J., Shea T. C., Cucchi C. A., Rosowsky A., Henner W. D., Frei E. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1987;47(2):388-393.

    Not in our library

  32. 32.

    Waud W. R. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res. 1987;47(24 Pt 1):6549-6555.

    Not in our library

  33. 33.

    de Graeff A., Slebos R. J., Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol. 1988;22(4):325-332.

    Not in our library10.1007/bf00254240 (opens in a new tab)

Cited by papers we hold2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.